MarginsXMarginsX
Home › Markets › Health Care › GTBP

GT Biopharma Inc. (GTBP)

GTBP trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$3.54
-1.81% on the day
Market cap
$7.3M
Nano cap
Revenue · 2020
$0
Prior year not contiguous
Net income · 2020
-$28.3M

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:Revenues), fiscal year ended 2020-12-31, https://www.sec.gov/Archives/edgar/data/109657/000165495421004295/0001654954-21-004295-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2020-12-31.

Profile

FieldValue
TickerGTBP on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO yearNot reported by the screener
SEC CIK0000109657
SEC industry codePharmaceutical Preparations
Incorporated inDE

Financials · 2020

LineValue
Revenue$0
Net income-$28.3M
Operating income-$6.8M
Net marginNeeds revenue and net income
Operating marginOperating income not reported
Revenue growthNo prior-year revenue to compare
Cash$5.3M
Total assets$5.7M
P/E (computed)Net income was not positive
P/S (computed)Needs market cap and revenue

Warning signs

Cash runway
4.1 months
$5.0M cash at June 30, 2026
Share count, 1 year
+1168.0%
2025-08-08 to 2026-08-10 · +3230.0% over 3 years
Going-concern doubt
Yes
10-Q filed August 14, 2026
Insider net buying, 12 months
$0
Through September 30, 2026
SignFindingSource
Going concernStates substantial doubt about continuing as a going concern.
"These factors raise substantial doubt about the Company's ability to continue as a going concern within one year of the date that the financial statements are issued."
10-Q 2026-08-14
Cash and burn$5.0M cash; operating cash flow -$3.6M a quarter.Report 2026-06-30
Shares outstanding1,804,380 (2026-08-10); 3,557,502 a year earlier; 40,639,688 three years earlier. 3y figure adjusted for splits (1-for-30 overall).Cover page 2026-08-10
Reverse splits, 3 years2; latest 1-for-25 on 2026-09-08Source 2026-09-08
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 0 424B5 takedownsNone on EDGAR
Exchange deficiency notices, 12 months2 (8-K item 3.01)8-K 2026-05-22
AuditorWeinberg & Company, P.A., Los Angeles, California, United StatesPCAOB Form AP 2026-03-05
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $0 on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q2 2026
2026-06-30
Not filed-$4.5M-$4.3M$5.0MNo debt tagsNeeds four quarters10-Q 2026-08-14
Q1 2026
2026-03-31
Not filed-$2.8M-$2.5M$8.9MNo debt tagsNeeds four quarters10-Q 2026-05-15
Q4 2025
2025-12-31
Not filed-$5.7M-$4.0M$6.8MNo debt tagsNeeds four quarters10-K 2026-03-02
Q3 2025
2025-09-30
Not filed$8.3M-$3.7M$2.5MNo debt tagsNeeds four quarters10-Q/A 2026-03-06
Q2 2025
2025-06-30
Not filed-$30.2M-$3.0M$5.2MNo debt tagsNeeds four quarters10-Q 2026-08-14
Q1 2025
2025-03-31
Not filed-$776K-$2.2M$2.4MNo debt tagsNeeds four quarters10-Q 2026-05-15
Q4 2024
2024-12-31
Not filed-$3.8M-$2.5M$4.0MNo debt tagsNeeds four quarters10-K 2026-03-02
Q3 2024
2024-09-30
Not filed-$3.4M-$2.7M$6.4MNo debt tagsNeeds four quarters10-Q/A 2026-03-06

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B32026-10-20
Latest annual report10-K2026-03-02
Latest quarterly / interim10-Q2026-11-16
Latest current report8-K2026-11-12
Latest proxyDEF 14A2026-10-13

Source: SEC EDGAR submissions feed, 885 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-15.8%
1 month-42.8%
3 months-49.9%
Year to date+373.9%
1 year+409.6%
From 52-week high-81.8%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
CURXCuranex Pharmaceuticals Inc$4.63-0.11%$7.3M
IMRNImmuron Limited$0.8996+2.23%$7.3M
LGVNLongeveron Inc.$2.14-14.06%$7.2M
UPCUniverse Pharmaceuticals Inc.$1.48-1.99%$7.4M
XCURExicure Inc.$1.07-0.93%$7.0M
MBRXMoleculin Biotech Inc.$7.14-9.28%$7.6M
TPSTTempest Therapeutics Inc.$0.3418-10.50%$6.8M
SNGXSoligenix Inc.$0.2882-10.22%$6.7M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier